Kornimate/medical-research-clean huggingface dataset:
evaluation of sars-cov-2 viral load of covid-19 patients after rinsing with oral antimicrobial mouthwashes

Conditions: Covid19

Summary: the aim of this study is to analyze the efficacy of oral disinfection with 0.075% cetylpyridinium chloride alone and 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate in reduction of the viral load of sars-cov-2 in the oral cavity. patients of both sexes, in the age-range between 18 and 90 years, diagnosed positive for sars-cov-2 by the rt-pcr method, and who demand oral hygiene care and other preventive and therapeutic dental procedures, will be included in this randomized clinical study.the study will comprise patients hospitalized in common beds, without mechanical ventilation - who will be divided into three groups. some of these protocols with the use of antimicrobial solutions are hoped to be efficient in reducing the viral load in the oral cavity. this is a factor that could contribute to reducing contamination of the environment caused by aerosols resulting from dental procedures, in addition to helping with the improvement in biosafety protocols against sars-cov-2.

each group of patients will receive specific interventions, as follows: 0.075% cetylpyridinium chloride mouthwash (group 1); 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate mouthwash (group 2), negative control, distilled water (group 3). to monitor the viral load, the following procedures will be performed: saliva collection, in time intervals before mouth rinsing with the solutions at baseline (t0), immediately after (t1), 30 min (t2), and 1 hour after mouth rinses (t3). sars-cov-2 will be quantified by real time quantitative reverse transcription polymerase chain reaction (rt-qpcr) assays.

Eligibility criteria:
inclusion criteria: * positive for sars-cov-2 by the rt-pcr method, * in common bed for minimum of 1 day and maximum of 5 days, * ensuring that patients are no more than 10 days since showing the first symptoms, * who are positive for sars-cov-2 in the first collection of oral fluid and saliva, and * who demands oral hygiene care and other preventive and therapeutic dental procedures. exclusion criteria: * pediatric patients, t * hose who tested negative for sars-cov-2 by the rt-pcr method at the time of recruitment or at the time of first oral fluid and saliva collection; * those who exhibit oral ulcerations and other erosive lesions in the oral mucosa, which contraindicate the use of cetylpyridinium; * patients who have bleeding in the oral cavity which prevents sample collections; patients who report history of allergy, irritations or other side effects derived from the use of these substances; * patients who do not adhere to oral care protocols or those in whom it was not possible to perform these procedures.
asthma in the elderly: the role of vitamin d

Conditions: Asthma in the Elderly

Summary: we will study whether taking vitamin d improves asthma control and spirometric values in elderly asthmatics.


Eligibility criteria:
inclusion criteria: * asthma, age of 65 years old or older exclusion criteria: * current smokers, subjects who smoked more than 10 pack/year, subjects taking digoxin, subjects with liver disease

Keywords: asthma, elderly, vitamin d
to determine long term efficacy and safety of asenapine in schizophrenic patient population (a7501012)(completed)(p05770)

Conditions: Schizophrenia

Summary: schizophrenia is a brain disease. the condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms. current management of schizophrenia focuses on the treatment of acute symptoms as well as long-term treatment aimed at preventing relapse after patients have experienced an improvement in acute symptoms. patients who discontinue treatment have a high likelihood of experiencing relapse within 1-2 years after an acute episode of schizophrenia. patients who remain on antipsychotic treatment have lower rates of relapse and have milder courses of exacerbation when relapse occurs.the symptoms of schizophrenia may be due to an imbalance in chemicals in the brain, primarily dopamine and serotonin, which enables brain cells to communicate with each other. asenapine may help to correct the imbalance in dopamine and serotonin. the purpose of this clinical trial is to evaluate the efficacy of asenapine in preventing relapse/impending relapse (hereafter referred to as 'relapse') in subjects who have been treated with asenapine for symptoms of schizophrenia for 26 weeks. in addition, to determine the safety and tolerability of asenapine for up to 1-year of treatment.


Eligibility criteria:
key inclusion criteria: * have a primary diagnosis of schizophrenia * history of at least 1 prior episode of acute schizophrenia in the 3 years preceding screening * history of schizophrenia requiring continuous antipsychotic treatment for at least 1 years preceding screening * clinically stable at the time of entry defined by at least a 4 week period of stable symptoms key exclusion criteria: * have an uncontrolled, unstable clinically significant medical condition * history of suicide attempt or significant violence to others in the past 2 years * a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse * current substance abuse/dependence * concurrent psychiatric disorder other than schizophrenia.
tate and pembrolizumab (mk3475) in mcrc and nsclc

Conditions: Colorectal Cancer; Lung Cancer

Summary: patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with trans-arterial tirapazamine embolization along with pembrolizumab.

this study is an open-label study to treat patients with refractory metastatic colorectal cancer and non-small cell lung cancer with liver metastasis. patients enrolled in the mcrc cohort will be randomized to receive study treatment trans-arterial tirapazamine embolization (tate)+pembrolizumab or fda-approved standard of care, such as tas-102 or regorafenib, and their overall survival (os) will be compared in the two cohorts as the primary endpoint. patients enrolled in the nsclc cohort will all receive study treatment tate+pembrolizaumb and overall response rate (orr) will be the primary endpoint.

Eligibility criteria:
inclusion criteria: * liver metastatic mss-mcrc or nsclc without egfr or akt mutations * mcrc progressed on at least two lines of standard chemotherapy; or * nsclc progressed on chemotherapy and an immune checkpoint inhibitor * measurable disease * ecog 0-1 * at least 4 weeks from prior chemotherapy and free from chemo-related toxicity * adequate organ function exclusion criteria: * prior organ transplantation * liver metastasis more than 50% * oxygen saturation less than 92% in room air * prior autoimmune disorder * cns metastasis * major gi bleeding in the last 2 months

Keywords: colorectal cancer nsclc pembrolizumab tirapazamine liver metastasis
uric acid, klotho and salt sensitivity in young adults born preterm

Conditions: Salt; Excess; Blood Pressure Disorders

Summary: the purpose of this research is to learn about how salt in the diet influences blood pressure in young adults who were born prematurely.

premature birth is an emerging and important risk factor for hypertension and cardiovascular disease, as both preterm birth rates and infant survival increase worldwide. hypertension and cardiovascular disease begin in early adulthood in individuals born prematurely, but the reasons especially in regard to the role of preterm birth are unknown. an improved understanding of why hypertension and cardiovascular disease occur in early adulthood in individuals born preterm will enable the development of prevention and treatment strategies to mitigate the burden of cardiovascular disease. investigators propose to investigate these relationships mechanistically in a clinical trial of subjects born preterm to establish the ssbp (salt sensitivity of blood pressure) phenotype and study its relationship to cvd (cardiovascular disease) compared to a control group of healthy term- born peers. investigators will then propose to determine if blocking ua (uric acid) formation improves ssbp and cardiovascular function in subjects born preterm.

Eligibility criteria:
inclusion criteria: * singleton birth * born at less than 34 weeks gestational age (preterm cohort) * born at greater than 36 weeks gestational age (term cohort) exclusion criteria: * twin birth * congenital anomalies or genetic syndromes * currently pregnant or breast feeding * subject-reported history of hypertension * current use of antihypertensive medications * active cancer * chronic kidney disease * heart failure * liver failure

Keywords: uric acid sensitivity salt sensitivity blood pressure influences
standard follow-up program (sfp) for head and neck cancer patients

Conditions: Head and Neck Cancer

Summary: the primary and general objective of the clinical introduction of the sfp as the current standard of care is to improve the quality of radiotherapy for head and neck cancer patients by reducing radiation-induced side effects without hampering treatment efficacy in terms of locoregional tumour control and overall survival and to systematically evaluate the beneficial effect of newly introduced radiation technology for this particular group of patients. the clinical introduction of the sfp will allow for a systematic and broad scale quality improvement cycle for head and neck cancer patients treated with radiotherapy. in fact, this methodology can be considered a kind of quality circle for the clinical introduction of new radiation techniques, aiming at continuous efforts for further improvement.

specific objectives * to develop, validate, and improve normal tissue complication probability (ntcp) models for a wide variety of acute and late radiation-induced side effects relevant for head and neck cancer patients (step 1); * to use the outcome of the ntcp models to better inform patients on the risks on acute and late toxicity; * to use the outcome of the ntcp models for the definition of dose constraints for radiotherapy treatment planning in current practice; * to use the outcome of the ntcp models for the development and investigation of the potential benefit of new and emerging radiation delivery technique, such as swallowing sparing intensity modulation radiation therapy (imrt) and proton radiotherapy. * to compare the outcome of new radiation delivery techniques that are clinically introduced with the current standard in terms of radiation-induced toxicity, patient-rated symptoms and quality of life and in terms of locoregional tumour control and overall survival

Eligibility criteria:
inclusion criteria: * all patients planned for curatively intended primary or postoperative radiotherapy will be included. at the first visit, patients are informed about the standard follow up program by the treating physician. exclusion criteria: * all patients planned for palliative radiotherapy will not be included in the sfp.

Keywords: acute toxicity late toxicity ntcp models proton therapy patient-rated outcomes quality of life
investigating kardiopac mobile app to improve physical fitness among cardiac rehabilitation patients

Conditions: Cardiac Rehabilitation; Exercise; Quality of Life

Summary: the purpose of this study is to sustain regular physical activity, improve health-related quality of life, improve resting blood pressure, improve anthropometrics, and improve adherence to prescribed cardiac rehabilitation sessions among individuals referred for cardiac rehabilitation (cr). numerous studies show that cr improves clinical outcomes in cardiovascular disease (cvd). exercise as a reliable adjunctive intervention, however, remains limited due to poor short- and long-term adherence. this proposed study will examine the effectiveness of the kura care kardiopac digital application plus cr to significantly sustain exercise adherence among cr patients, as compared to standard of care alone.


Eligibility criteria:
inclusion criteria: 1. referred to the university of california san diego health cardiac rehabilitation center for 36-72 sessions of intensive cardiac rehabilitation for one of the following medical conditions: myocardial infarction, coronary artery bypass surgery, stable angina, heart valve repair or replacement, coronary angioplasty or stenting, congestive heart failure, heart transplant, or peripheral arterial disease 2. able to give informed consent in english 3. able to perform study assessments as described 4. resting bp\<180/110 mmhg 5. able to perform light to moderate exercise 6. have not had a fall during the previous 6 months resulting in an injury 7. clinical staff's permission to participate, including their assessment that participant is a good candidate for this research study 8. ability to complete written or app-based surveys 9. owns an apple or android mobile telephone capable of downloading and running the app exclusion criteria: 1. referred to cr following ventricular assist device procedure 2. angina not adequately managed with nitrates 3. oxygen-dependent chronic obstructive pulmonary disease 4. recent stroke or significant cerebral neurologic impairment that would interfere with participation. 5. unable to operate a bp device
isoamyl 2-cyanoacrylate in the urethro-cutaneous fistula repair

Conditions: Hypospadias

Summary: cyanoacrylate has an impact that may aid in the successful repair of urethra-cutaneous fistula (ucf) that occur after hypospadias surgical repair

hypospadias is a common congenital urological birth defect. urethro-cutaneous fistula (ucf) is the most common complication of surgical repair hypospadias and it remains the primary concern of surgeons dealing with hypospadias repair. cyanoacrylate has been reported to enhance the healing process. this study tries to evaluate the clinical impact of cyanoacrylate on the repair of urethro-cutaneous fistula after surgical repair of hypospadias this study evaluates the impact of using cyanoacrylate as an interposition substance in surgical repair of ucf after hypospadias in comparison to the classic surgical repair technique

Eligibility criteria:
inclusion criteria: * patients with urethro-cutaneous fistula regardless of their age were included in our study. exclusion criteria: * patients with fistula size more than 5 mm * multiple fistulas * uncorrected obstruction distal to the fistula * necrotic tissue * active infection at the fistula site * severely scarred skin * deficient dartos around the fistula * fistulas more proximal to the mid penile position * recurrent fistulas * previous history of hypersensitivity to cyanoacrylate-based products

Keywords: isoamyl 2-cyanoacrylate urethrocutaneous fistula fistula repair hypospadias
implementation of the low risk ankle rule

Conditions: Ankle Injury

Summary: ankle injuries are a very common injury in children. each year approximately 35000 kids present to ontario emergency departments (ed) with this problem. right now, about 90% of these children get x-rays of the injured ankle, even though only 12% of these x-rays show a break in the bone. some excellent research has created some rules that doctors can use to help them decide which children really need x-rays. unfortunately, even though these rules have been proven to safely reduce x-rays by as much as two-thirds, most doctors are not using these rules. therefore, this study will be the first to put the best paediatric ankle x-ray rule, the low rick ankle rule, into physician practice in eds. our main goal is to determine how much we can reduce ankle x-ray rates in eds that use this rule regularly versus those that do not. if we show that doctors can safely use this rule regularly and the number of ankle x-rays will be significantly less, this will lessen unnecessary potentially harmful radiation exposure in children, these children will spend less time in an ed, and the health care system will save money.


Eligibility criteria:
inclusion criteria: * all otherwise healthy children between the ages of 3 and 16 years of age that present to the participating eds with an isolated acute (\< 72 hours) blunt ankle injury due to any mechanism of injury will be eligible for the study. the age criteria were chosen to match those ages in which the lrar was validated. exclusion criteria: 1. children with ankle injuries who were referred from outside the hospital with radiographs. 2. children with ankle injuries who returned for reassessment of the same ankle injury. 3. children with open wounds on their ankle and/or foot 4. all children at risk for pathological fractures such as those with congenital or acquired generalized bony disease (appendix i). clinical presentation and risks in these cases may be altered. 5. congenital anomalies of the feet and/or ankles (eg club feet, tarsal coalition). these abnormalities may have features which may complicate clinical assessment. 6. patients with known coagulopathies. underlying hemarthrosis may complicate clinical assessment. 7. patients with cognitive and/or developmental delay. these patients may not localize pain. 8. injuries greater than 72 hours old. the signs and symptoms of the most common fracture, the salter-harris i fracture of the distal fibula, may be diminished. our ability to make this clinical diagnosis with confidence may thus be compromised. 9. recent history of surgery or closed reduction of the same ankle within the last 3 months. these prior events may confuse current presenting symptomatology and ability to weight-bear and recover normally. 10. patients with low risk injuries who do not have phone or electronic mail access and/or have an insurmountable language barrier. this will preclude follow up.

Keywords: paediatric emergency department ankle injury low risk ankle rule
pharmacokinetics of trans-resveratrol based nutritional supplement and its three metabolites in human eyes and blood

Conditions: Eye Disease

Summary: there is blood-eye barrier in eyes,but some oral medicines can enter in the tissues of eyes. the primary objective of the study is to study the pharmacokinetics of trans-resveratrol and its three metabolites in human eyes and blood

this was a single-blind, randomised study investigating single oral dose of longevinex in two groups of about 20 patients with rhegmatogenous retinal detachment retinal detachment（males and females).the subjects received 100mg longevinex everyday,a total of three days before surgery.

Eligibility criteria:
inclusion criteria: 1. patients with rhegmatogenous retinal detachment. 2. male and female patients 18-60 years of age. 3. nonsmokers or who smoke\<10 cigarettes/day. 4. bmi ranging from 19 to 30 kg/m\^2 were eligible for the study. 5. patients were considered to be healthy on the basis of electrocardiogram (ecg), and clinical laboratory safety tests (haematology, plasma biochemistry, urinalysis and hepatitis b, hepatitis c and hiv serology) performed at screening. 6. women use measures to avoid conception during the study period (e.g. oral contraceptives, intrauterine devices \[iuds\], and condoms). 7. avoid ingesting grapefruit, grapefruit juice or other grapefruit juice containing products, and any herbal-based nutrient supplement or prescribed medications( grapefruit, cranberry, blueberry products, peanuts and peanut butter, grape and grape products, and red wine ) during the same period of time. 8. patients should abstain from alcohol-containing beverages at least two days prior to and during the study. exclusion criteria: 1. uncontrolled blood pressure exceeding diastolic pressure of 100 mm hg (sitting) during the screening period and uncontrolled diabetes mellitus 2. participation in another simultaneous medical investigation or trial 3. renal failure requiring dialysis or renal transplant or liver dysfunction history of other disease,or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications.5.iop over 30 mmhg. 4. any previous retinal laser photocoagulation to the study eye in treatment naive. any previous intravitreal injection in study eye (triamcinolone or other) in treatment naive. 5. any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery). intracapsular cataract extraction (posterior capsule needs to be present). 6. aphakia or absence of the posterior capsule in the study eye, structural damage to the center of the macula in the study eye preexisting to crvo likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s). -
couple-based intervention for patients with head and neck cancer and their partners

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to determine whether a brief couple-based supportive intervention effectively assists patients and their partners coping with the challenges of head and neck cancer.

this intervention will adapt a well-validated cognitive-behavioral therapeutic approach in a four-session intervention to teach patients and partners specific couple-based cancer-focused support skills. in addition, in order to gather information on outcome variables, couples will complete three assessments during the course of treatment (pre-treatment, following treatment, and six month follow-up). these assessments will include questionnaire measures as well as couple communication whereby couples will participate in two videotaped conversations whereby one partner of the couple discusses a concern and the other member of the couple provides support. we also will implement a "daily diary" assessment whereby day-to-day psychological and physical symptoms experienced by the patient and partner will be assessed and daily effects of the intervention can be analyzed. patients and partners will participate in the daily diary portion of the study following the post-assessment. they will be emailed an electronic link to a brief questionnaire daily for 7 days. the items in this daily assessment will comprise questions that are part of the general assessment measures such as dyadic coping, spousal support, and relationship satisfaction. the patient will also complete questions about pain and fatigue.

Eligibility criteria:
inclusion criteria: * recently diagnosed with head and neck cancer receiving chemotherapy and/or radiation therapy * no history of cancer within past 3 years (other than basal cell) * living with partner in a committed relationship at least 6 months * patient and partner speak and read english exclusion criteria: * serious cognitive or emotional issues that preclude full participation in study

Keywords: couples head and neck cancer oncology spousal support